Oral Infigratinib Therapy in Children with Achondroplasia
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F25%3A00142909" target="_blank" >RIV/00216224:14110/25:00142909 - isvavai.cz</a>
Result on the web
<a href="https://www.nejm.org/doi/full/10.1056/NEJMc2504219" target="_blank" >https://www.nejm.org/doi/full/10.1056/NEJMc2504219</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1056/NEJMc2504219" target="_blank" >10.1056/NEJMc2504219</a>
Alternative languages
Result language
angličtina
Original language name
Oral Infigratinib Therapy in Children with Achondroplasia
Original language description
Savarirayan et al. report that oral administration of the FGFR inhibitor infigratinib to children with achondroplasia improves longitudinal growth and skeletal proportions. Their study represents an important advance over current vosoritide therapy in terms of efficacy (higher annualized height velocity) and administration (oral vs. daily injections). However, the boundaries of achondroplasia therapy can be pushed even further.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30218 - General and internal medicine
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
New England journal of medicine
ISSN
0028-4793
e-ISSN
1533-4406
Volume of the periodical
392
Issue of the periodical within the volume
23
Country of publishing house
US - UNITED STATES
Number of pages
1
Pages from-to
2388
UT code for WoS article
001668941500002
EID of the result in the Scopus database
2-s2.0-105009390605